Janssen buys autoimmune licence from Novo Nordisk

Janssen Biotech acquires licence from Novo Nordisk for a development programme focused on autoimmune diseases


Terms of the agreement have not been disclosed

Novo Nordisk A/S has signed an agreement with Janssen Biotech (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed.

The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Department of Justice Antitrust Division and the Federal Trade Commission.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email